Company intelligence / Profile preview

PMGC Holdings Inc.

Newport Beach, California, United Statespmgcholdings.com ↗

Ownership: Public · ELAB
Employees: ~3
Development stage: Preclinical

Overview

Developing EL-22, a lead asset leveraging an engineered probiotic approach to address obesity's issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Engineered probiotics
Industry: Biotech

Drug pipeline

2 assets

EL-22

Pre-clinical

Indications: Obesity, Muscle loss

1 more asset in the full pipeline.

Request access →

Partnerships

Canadian Universities

Beyond the preview

Go deeper on PMGC Holdings Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMGC Holdings Inc..

Explore the full profile